Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Invested Capital (2020 - 2025)

Historic Invested Capital for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $3.4 million.

  • Evoke Pharma's Invested Capital fell 2336.15% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 2336.15%. This contributed to the annual value of $7.0 million for FY2024, which is 37284.0% up from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Invested Capital is $3.4 million, which was down 2336.15% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Invested Capital registered a high of $7.8 million during Q1 2021, and its lowest value of -$2.6 million during Q4 2023.
  • Over the past 5 years, Evoke Pharma's median Invested Capital value was $4.1 million (recorded in 2022), while the average stood at $3.7 million.
  • In the last 5 years, Evoke Pharma's Invested Capital surged by 169646.49% in 2021 and then tumbled by 16315.2% in 2023.
  • Over the past 5 years, Evoke Pharma's Invested Capital (Quarter) stood at $3.6 million in 2021, then rose by 14.9% to $4.1 million in 2022, then plummeted by 163.15% to -$2.6 million in 2023, then soared by 372.84% to $7.0 million in 2024, then plummeted by 52.23% to $3.4 million in 2025.
  • Its Invested Capital stands at $3.4 million for Q3 2025, versus $4.4 million for Q2 2025 and $5.8 million for Q1 2025.